A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.

Patricia LoRusso,Mrinal M. Gounder,Manish R. Patel,Noboru Yamamoto,Todd M. Bauer,Scott A. Laurie,Rolf Grempler,Teffany Davenport,Junxian Geng,Maren Rohrbacher,Mehdi Lahmar

A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.

2021

Patricia LoRusso
Mrinal M. Gounder
Manish R. Patel
Noboru Yamamoto
Todd M. Bauer
Scott A. Laurie
Rolf Grempler
Teffany Davenport
Junxian Geng
Maren Rohrbacher
Mehdi Lahmar

3016Background: BI 907828, a highly potent and orally administered MDM2-p53 antagonist, showed antitumor efficacy in vivo, especially in TP53 wild-type MDM2-amplified de-differentiated liposarcoma ...

Keywords:

dose escalation
Medicine
in patient
Pharmacology
Liposarcoma
mdm2 p53
Antagonist

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations